AGT-182 is an investigational enzyme replacement therapy engineered by the fusion of the iduronate-2-sulfatase (IDS) enzyme and a human insulin receptor monoclonal antibody.
AGT-182 is an investigational enzyme replacement therapy engineered by the fusion of the iduronate-2-sulfatase (IDS) enzyme and a human insulin receptor monoclonal antibody.
No indication information available.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.